Content Type: Article

  • RAPID pathway speeds coverage but raises evidentiary stakes

    RAPID pathway speeds coverage but raises evidentiary stakes

    ARTICLE / CLIENT ALERT

    RAPID pathway speeds coverage but raises evidentiary stakes

    April 28, 2026

    Read time: 6 min

    Key takeaways
    Overview

    On April 23, 2026, the Centers for Medicare & Medicaid Services (CMS) and the US Food and Drug Administration (FDA) announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway for certain FDA-designated Breakthrough Devices. RAPID is expected to provide predictable national Medicare coverage at or soon after a device’s launch.

    Under most national Medicare coverage pathways, CMS requires FDA authorization before starting the national coverage determination (NCD) process. This process typically takes nine to 12 months from the time CMS chooses to take up a topic. However, the gap between FDA authorization and Medicare national coverage is frequently longer because of the large number of requests and limited CMS resources in this area. Thus, many new technologies come to market without predictable coverage, placing beneficiaries and healthcare systems at financial risk.

    RAPID is CMS and FDA’s latest effort to close the gap (an earlier effort, the Parallel Review pathway, is still available). Under RAPID, CMS and FDA will collaborate during the FDA review process to provide input to medical device companies about the evidence needed for both regulatory authorization and national Medicare coverage. Participation in RAPID will not change or reduce FDA’s standards for approval, authorization, or clearance. However, early CMS involvement may influence study design, including endpoint selection, patient population, and patient size, which in turn may shape the evidentiary package submitted to FDA.

    The RAPID coverage pathway will be available to Class III devices and certain Class II devices that participate in the FDA Total Life Cycle Advisory Program (TAP). Devices must be FDA-designated Breakthrough Devices that address unmet medical needs among Medicare beneficiaries. Devices must be the subject of an Investigational Device Exemption (IDE) study that enrolls Medicare beneficiaries and with clinical health outcomes agreed upon by FDA and CMS. TAP is open to ophthalmic, cardiovascular, neurological and physical medicine, orthopedic, and radiologic health devices. Later in 2026, TAP will expand to other types of devices.

    Once in RAPID, MedTech companies must decide whether to accept likely higher evidentiary standards needed by CMS and potentially increased trial size, length, and cost in return for predictable coverage. Depending on CMS’s requirements, the risk of trial failure also may increase. On the other hand, conducting a successful, more rigorous trial will result in near-immediate national Medicare coverage and may improve the likelihood of faster coverage by commercial payers and more favorable treatment in clinical guidelines.

    In depth

    Participation in RAPID will involve strategic trade-offs. Because CMS’s (and other payers’) evidentiary bar is higher than FDA authorization needs, IDE studies for devices in the RAPID program may be more robust, with greater participation by Medicare beneficiaries, more patient-outcomes-based endpoints, and longer follow-up times than most studies supporting devices solely for FDA authorization. Your risk of trial failure may consequently be higher, depending on the circumstances.

    The following questions may be helpful to consider:

    • Do you think it’s worthwhile to accept CMS suggestions?
    • How much will adapting your IDE study as requested by CMS add to the study’s cost
    • How much longer will the study take?
    • Will the trial fail based on the endpoints CMS has requested?
    • Will your pricing strategy change to account for higher costs and longer time to get to market?
    • Will the feedback be clear as to which endpoints FDA requires for authorization and which CMS requires for an NCD?
    • If so, what happens if you meet FDA endpoints but fail to meet CMS endpoints?
    • If not, and if they are “joint” endpoints, are you willing to accept the risk of failure? Why accept this risk?

    CMS may in some cases adopt a more flexible approach to pre-market evidence generation and opt to require evidence generation through post-market studies, leveraging either any FDA-required post-market approval studies or other post-market surveillance. In such cases, the CMS coverage determination could take the form of an NCD with continuing evidence generation requirements.

    If you accept CMS and FDA’s evidence generation strategy, CMS will issue a proposed NCD on the same day as FDA authorization. CMS will then accept public comments on the proposed coverage decision for 30 days. CMS notes that this approach could result in a coverage decision in as little as two months, a marked contrast with the much lengthier current process.

    An NCD will ensure consistent national coverage for all Medicare beneficiaries in fee-for-service (FFS) coverage. In addition, all Medicare Advantage (MA) plans are required to follow NCDs, so MA plans will not be able to issue noncoverage policies that conflict with FFS policy (although MA plans may still impose prior authorization requirements). Your customers will be able to assure their Medicare patients that Medicare will cover the new technology. Your sales teams will be able to assure your customers that they will be reimbursed for using your new technology following the requirements in the NCD.

    Many questions remain to be answered. For example:

    • Must your device fall into an existing Medicare benefit category to leverage RAPID
    • Can you withdraw from RAPID if you are not willing to accept CMS’s evidence requirements?
    • Will you have input on the draft NCD that CMS will publish on the day you receive market authorization?
    • To what extent might the proposed NCD deviate from the scope of FDA-authorized labeling for the device?
    • Will CMS and FDA have sufficient resources to provide input and meet their timing promises to participants in the RAPID pathway?
    • Will your participation be kept confidential?
    • Will CMS conduct a literature review to identify gaps in evidence and if so, will the review be made public if you withdraw?

    FDA and CMS likely will start to provide answers to these and other questions in the forthcoming Federal Register notice. The notice will be open for public comments for 60 days.

    The McDermott difference

    Once the notice is published, McDermott+ and McDermott Will & Schulte can support your analysis and assist in developing comments to FDA and CMS.

    Authors

    James R. Ravitz

    Partner

    Washington, DC

    Michael W. Ryan

    Partner

    Washington, DC

    Paul S. Gadiock

    Partner

    San Francisco

    More insights

  • Trending in Telehealth: March 2026

    Trending in Telehealth: March 2026

    ARTICLE

    Trending in Telehealth: March 2026

    Apr 28, 2026

    Read time: 6 min

    Key takeaways
    Overview

    Trending in Telehealth highlights monthly state legislative and regulatory developments that impact the healthcare providers, telehealth and digital health companies, pharmacists, and technology companies that deliver and facilitate the delivery of virtual care.

    Trending in March:

    • Expansion of telehealth across additional professions (veterinary medicine, genetic counseling, social work, naturopathic medicine).
    • Licensure flexibility and cross‑state practice, including reciprocity and compacts.
    • Telehealth integration into emergency, rural, and specialty-care models.

    A CLOSER LOOK

    Proposed legislation and rulemaking:

    • Both chambers of the Virginia legislature passed HB 1391 establishing a Sickle Cell Coordinated Access Network, which among other things, would allow specialists to provide telehealth consultations on pain management, treatment protocols, and care coordination.
    • In Florida, both chambers passed SB 688, which would revise existing laws related to naturopathic medicine, including adding licensed naturopathic doctors to the term “telehealth provider.”
    • In West Virginia, the first chamber passed SB 677 allowing genetic counselors to provide telehealth services.
    • In Colorado, the first chamber passed HB 1069, clarifying that “emergency services” includes transportation of an individual to an appropriate location other than a hospital or community integrated healthcare service agency. The use of telemedicine when an insured person has encountered an ambulance service or agency to prevent the need to transport the person to an emergency department is included in the definition of “emergency services,” which services are required to be made available to insured persons 24 hours per day, 7 days per week.
    • The first chamber of the Hawaii legislature passed HB 2558 aimed at addressing Hawaii’s physician shortage by allowing out-of-state doctors to establish initial physician-patient relationship with Hawaii residents through telehealth services under certain conditions.
    • Both chambers of the Georgia legislature passed HB 1195 amending Georgia law to allow licensed veterinarians and veterinary technicians to practice telemedicine, teleadvice, and teletriage without requiring an established veterinarian client patient relationship.
    • The first chamber of the Arizona legislature passed SB 1286 permitting veterinarians to establish a client-patient relationship through electronic means.
    • In Hawaii, the first chamber passed HB 1871, which would establish the Maternal Health Monitoring Pilot Program within the state Department of Health to offer eligible participants improved maternal healthcare through remote patient monitoring for maternal hypertension and maternal diabetes.
    • Both chambers of the Kentucky legislature passed HB 424, which regulates the provision of social work services via telehealth in Kentucky by clarifying that social work may be practiced in person, through telehealth, or through other technology, but only by appropriately licensed individuals, those holding a temporary permit, or practitioners authorized under the Social Work Licensure Compact. The bill defines “telehealth” by reference to existing Kentucky law and establishes detailed requirements for telehealth practice, including informed consent, confidentiality, accessibility for individuals with disabilities, proper use of HIPAA‑compliant technology, identity and location verification, documentation, and adherence to the same standards of care as in‑person services. It also addresses cross‑border telehealth by permitting licensed out‑of‑state and multistate practitioners to provide services to Kentucky clients.
    • The Board of Dental Examiners of Nevada proposed a rule establishing regulations around teledentistry.

    Finalized legislation and rulemaking:

    • New Mexico’s governor signed into law HB 306, which prohibits healthcare providers and systems in New Mexico from charging facility fees directly to patients for preventive healthcare, vaccinations, and telehealth services, while exceptions are made for inpatient and emergency settings.
    • The South Carolina governor signed H 3223 into law, which governs the use of telehealth for veterinary services. The law went into effect on March 9, 2026.
    • West Virginia’s governor signed HB 5458 into law, allowing a genetic counselor to provide telehealth services and instructing the Board of Medicine to promulgate a rule for legislative approval establishing the standard of care for the provision of genetic counseling via telehealth. The law goes into effect on June 7, 2026.
    • The Maine governor signed LD 1583 into law allowing home healthcare providers in Maine to accept orders from physicians licensed in other states, removing the need for those physicians to be licensed in Maine for this purpose. Orders are limited to 90 days and pertain solely to home healthcare services, excluding hospice care. Healthcare providers must be certified by the US Department of Health and Human Services, and the ordering physicians must conduct an in-person examination before issuing orders. Removing previous requirements, out-of-state physicians don’t need to contact Maine patients’ primary care providers and can provide related telehealth services only to those specific patients.
    • Utah’s governor signed SB 150 into law, which requires that the Office of Professional Licensure Review conduct a scope of practice review to determine whether to recommend that a regulated healthcare occupation should incorporate an innovation into the regulated healthcare occupation’s practice in a way that would expand the scope of the regulated healthcare occupation’s license. “Upgrade in technology” means an addition or change to artificial intelligence; a medical device; medical equipment; a medical tool; or any other technology the office determines has the potential for a healthcare practitioner to use in the healthcare practitioner’s practice.
    • Utah’s governor also signed HB 389 into law, amending provisions related to medical cannabis, including allowing any patient to obtain a medical cannabis patient card from a recommending medical provider through a virtual visit.

    Compact activity:

    • The following states introduced bills to enact licensure compacts:

    Why it matters:

    • States continue to normalize telehealth as a core mode of service delivery across a widening range of licensed professionals, going well beyond traditional physician‑based care. Legislative activity in March reflects deliberate efforts to clarify supervision standards, authorize remote establishment of patient relationships, and expressly include telehealth within statutory scopes of practice. This provides greater certainty for providers and platforms operating in niche or emerging care models, particularly in veterinary, genetic counseling, and social work.
    • Licensure mobility and reciprocity remain a major policy priority as states seek to address workforce shortages and access gaps. Measures allowing out‑of‑state practitioners to deliver telehealth services, recognize compact privileges, or rely on licensure waivers underscore a sustained shift toward facilitating cross‑border care rather than limiting practice to in‑state licensure alone.
    • Policymakers are increasingly leveraging telehealth to address access challenges in rural, emergency, and underserved settings. From permitting general supervision via telecommunications in critical access facilities to incorporating telemedicine into emergency medical services and maternal health monitoring programs, March trends show telehealth being embedded into public health infrastructure rather than treated as a standalone or temporary alternative to in‑person care.

    Telehealth is an important development in care delivery, but the regulatory patchwork is complicated. The McDermott Will & Schulte digital health team works alongside the industry’s leading providers, payors, and technology innovators to help them enter new markets, break down barriers to delivering accessible care, and mitigate enforcement risk through proactive compliance.

    Authors

    Lisa Mazur

    Partner

    Chicago

    Amanda Enyeart

    Partner

    Chicago

    Abygail Hoey

    Associate

    New York – One Vanderbilt Avenue

    More insights
    Endnotes

  • European Union’s landmark anti-corruption directive sets unified rules on offences and sanctions

    European Union’s landmark anti-corruption directive sets unified rules on offences and sanctions

    ARTICLE / CLIENT ALERT

    European Union’s landmark anti-corruption directive sets unified rules on offences and sanctions

    28 April, 2026

    Read time: 11 min

    Key takeaways
    Overview

    The EU fight against corruption

    On April 21, 2026, the Council of the European Union gave its final approval to the so-called “Anti‑Corruption Directive”, completing the European Union’s first comprehensive and binding criminal law framework to address corruption across all Member States. This step confirms the direction already outlined by the European Commission’s earlier initiative to update and strengthen the EU anti‑corruption legislative framework (the so‑called “Anti‑Corruption Package“), to which we referred in our client alert in 2023, and marks the transition towards a fully harmonized set of EU‑wide rules on corruption. The Anti-Corruption Directive replaces a fragmented set of EU legacy instruments that had so far hampered a coherent and effective response to corruption across the European Union and which aims to remove existing enforcement gaps and obstacles to cooperation between authorities in different Member States. This goal will be pursued through the introduction of harmonised offences, minimum sanctions for natural persons, and a robust turnover‑based sanctioning regime for legal entities, while also mandating national prevention strategies and dedicated anti‑corruption bodies.

    The Anti-Corruption Directive, as part of the EU Anti-Corruption Package, is also a response to the results of the most recent Commission‑led surveys and analysis, according to which Europeans and European companies believe that corruption is widespread, that is may affect public procurement and that the cost of corruption seems to be increasing.

    The key features of the Anti-Corruption Directive are outlined below.

    In depth

    Harmonised definitions of corruption offences

    The Anti-Corruption Directive provides for harmonized definitions of a broad range of criminal offences that Member States must transpose into their national laws, including the following.

    • Bribery in the public sector: The Anti-Corruption Directive reflects the traditional distinction between public active corruption, which consists in the promising, offering or giving an undue advantage to a public official with the intention of influencing the performance of their duties, and public passive corruption, in which it is the public official who demands or receives an undue advantage in exchange for performing (or refraining from performing) an act in exercise of their official functions. What constitutes a “public official” is very broad and applies to all individuals performing a public service function not only within the European Union or a Member State, but even within a “third country” (i.e. a non-EU country) and including in state-owned or state-controlled entities, as well as in asset-management foundations and privately owned companies performing public service functions.
    • Bribery in the private sector: The Anti-Corruption Directive also mirrors the distinction between active and passive corruption in the private sector. Private active corruption consists of promising, offering or giving an undue advantage to a person who performs managerial or working functions for a private sector entity, with the intention of inducing that person to act, or refrain from acting, resulting in a breach of their professional duties. On the other hand, private passive corruption, occurs when such a person requests, receives or accepts the promise of an undue advantage in exchange for performing (or omitting) an act, resulting in a breach of their duties.
    • Trading in illicit influence: An offence committed when a person intentionally offers, promises or gives an undue advantage to someone in order for that person to exert improper influence over the actions or omissions of a public official in the exercise of their functions, with the aim of obtaining an undue benefit from that official. It also covers the reverse situation, where a person solicits, receives or accepts an undue advantage (or the offer or promise of such an advantage_ in exchange for exerting improper influence over a public official’s decision-making. This offence applies irrespective of whether the influence is real or merely presumed, whether it is actually exercised or not, and whether it succeeds in producing the intended outcome or not.
    • Unlawful exercise of public functions: An offence encompassing serious violations of the law committed by a public official through an action or omission in the exercise of their duties. This offence captures situations in which an official deliberately misuses powers conferred upon them in a manner that results in a serious breach of legal obligations, irrespective of whether any direct exchange of money or other undue advantage occurs.
    • Misappropriation: Defined as the intentional commitment, disbursement, misappropriation or use, by a public official (or, in the context of economic, financial or business activities, by a person performing managerial or operational functions within a private‑sector entity), of property entrusted to them for management, for purposes other than those for which it was intended, where such conduct is carried out for the benefit of that public official or of another person or entity, or results in damage to the financial interests of the public or private entity concerned.

    Corporate liability standard

    Companies can be held liable when offences are committed for their benefit by individuals who hold a leading position within the legal entity, acting individually or as part of a corporate body, where any such person has:

    • Power of representation of the legal person
    • Authority to take decisions on behalf of the legal person; or
    • Authority to exercise control within the legal person

    Thus, liability can be the result of a mere lack of supervision or control by a leading person (e.g. senior executives), where any such failure has enabled the commission of the offence, for the benefit of the entity, by a person (e.g., an employee) acting under its authority.

    In this context, the Anti-Corruption Directive clarifies that offences giving rise to corporate liability include all corruption related crimes, while excluding the offence of unlawful exercise of public functions under Article 7.

    Importantly, corporate liability under the Anti-Corruption Directive does not replace or exclude individual criminal responsibility. Both coexist and may be pursued in parallel.

    Sanctioning framework for legal entities: The turnover-based model

    The Anti-Corruption Directive requires that for some serious offences (public and private corruption and misappropriation), fines must not be set below 5% of the entity’s global turnover in the financial year preceding the offence or the decision imposing the fine or, alternatively, a fixed amount of €40 million, while for other offences (trading in influence, obstruction of justice and enrichment through corruption) fines must reach at least 3% of the company’s global turnover or a fixed amount of €24 million.

    These monetary sanctions may be accompanied by a broad range of additional measures, including:

    • Exclusion from public aid and funding
    • Exclusion from tenders, grants, concessions and licenses
    • Temporary or permanent business bans
    • Withdrawal of permits and authorisations
    • Termination of the contract under which the offence occurred
    • Judicial supervision
    • Compulsory liquidation
    • Closure of premises used to commit the offence
    • Publication of the judicial decision (subject to privacy safeguards)

    For companies operating in regulated sectors or dependent on public procurement, a conviction may have far-reaching consequences, potentially affecting their ability to continue operating.

    This represents a structural shift from the traditional quota-based model towards the consolidation of turnover-based sanctions, consistent with the European Union’s sanctioning criteria set under the GDPR or the Directive (EU) 2024/1226 for the criminalization of violations of EU restrictive measures, which we discussed in our previous alert).

    Jurisdiction and extraterritorial application

    Article 18 of the Anti-Corruption Directive significantly expands jurisdictional reach beyond traditional territorial and nationality principles (i.e., territorial jurisdiction and jurisdiction based on the offender’s nationality, the so-called active personality principle), enabling Member States to assert jurisdiction over offences committed abroad where a sufficient nexus exists with their territory, including through the offender’s habitual residence, the victim’s nationality (and habitual residency) or,most notably, the benefit gained by legal entities established or operating within their jurisdiction.

    The Anti-Corruption Directive also addresses conflicts of jurisdiction, requiring Member States to cooperate in determining the most appropriate forum for prosecution, with the possibility of referring disputes to European Union Agency for Criminal Justice Cooperation (Eurojust).

    Limitation periods

    The Anti-Corruption Directive also introduces minimum limitation periods designed to ensure the effective enforcement of corruption offences, in light of their inherently complex and often covert nature. As mentioned in the Anti-Corruption Directive, corruption offences are difficult to detect, investigate and prove, often involving cross-border elements and sophisticated concealment mechanisms and “[t]he longer it takes to detect a corruption offence, the more difficult it is to uncover evidence.”

    Against this backdrop, Member States are required to provide for sufficiently long limitation periods both for the prosecution phase (at least eight or five years, depending on the offence) and for the enforcement of final convictions (up to at least ten years). By setting minimum thresholds, the Anti-Corruption Directive seeks to ensure that authorities have adequate time to uncover evidence, conduct complex investigations and ultimately secure and enforce convictions.

    Whistleblowers’ protection

    The Anti-Corruption Directive places significant emphasis on the role of whistleblowers as a key enforcement mechanism in the fight against corruption. Due to the difficulty in detecting corruption through traditional investigative means, individuals operating within organizations are frequently the primary source of relevant information.

    In this context, the Anti-Corruption Directive confirms the applicability of the so-called “Whistleblowing Directive” to reports concerning corruption offences falling within its scope, thereby ensuring, namely,  access to confidential reporting channels and protection against retaliation.

    The Anti-Corruption Directive requires Member States to put in place appropriate measures to ensure that anyone that reports offences, provides evidence or otherwise cooperates with the relevant authorities is granted effective protection, as well as access to support and assistance, in accordance with national law.

    From a practical standpoint, this reinforces the centrality of internal reporting systems within corporate compliance frameworks, which are no longer merely procedural safeguards but increasingly function as critical tools for early risk detection, mitigation, and potential defence against corporate liability.

    Mitigating factors

    The Anti-Corruption Directive requires Member States to ensure that an offender’s cooperation with the relevant authorities is recognised as a mitigating circumstance, where the information provided proves essential to uncover evidence or identify the perpetrators of the offence that would otherwise have remained undiscovered.

    As to legal entities, the Anti-Corruption Directive clarifies that the adoption and effective implementation of internal control and compliance systems may be taken into account as a mitigating factor in setting sanctions, without prejudice to national regimes that attribute a broader legal effect to such systems. This approach preserves Member States’ discretion to recognise liability ‑ excluding effects for compliance programmes, as exemplified by either the Italian Legislative Decree No. 231/2001, under which an effectively implemented Organisational, Management and Control Model may exclude the entity’s liability, or the French Sapin II law and related decrees, which require the implementation of compliance programs, the absence of which may be considered an aggravating factor when setting sanctions.

    From a practical perspective, the final determination of the sanction is left to the court’s discretion, assessing the relevance of any mitigating circumstances against the specific case. In this context, the Anti-Corruption Directive makes clear that compliance systems must be effectively operational, and not merely formal (“window dressing”), thereby placing decisive emphasis on the substantive effectiveness of internal controls and procedures rather than on their mere formal adoption.

    Prevention of corruption

    Beyond criminalization, the Anti-Corruption Directive emphasizes prevention and systemic reform. Member States will be required to adopt and periodically update national anti corruption strategies, carry out structured risk assessments and reinforce transparency mechanisms relating to conflicts of interest and political financing. They must also ensure that one or several bodies or organizational units is tasked with the prevention of corruption are in place and possesses the necessary expertise to fight against corruption. Reinforced cooperation with bodies such as the European Anti-Fraud Office (OLAF), Europol, Eurojust and the European Public Prosecutor’s Office (EPPO) is intended to improve enforcement, particularly in cross-border investigations.

    Next steps: Transposition timeline and key takeaways

    The Anti-Corruption Directive will enter into force 20 days after its publication in the Official Journal of the European Union. Member States will have 24 months to transpose the Anti-Corruption Directive into national law.

    From a corporate perspective, the Anti-Corruption Directive significantly raises the stakes and that is why companies should not wait. Early alignment will be crucial, including by:

    • Conducting a targeted gap analysis, aimed at assessing the alignment of existing compliance frameworks with the offences, triggers and sanctioning criteria introduced by the Anti-Corruption Directive, as well as identifying areas where current controls may prove insufficient in light of the enhanced EU standards, except in Member States that already have such legal frameworks in place or more stringent ones
    • Reviewing or updating codes of conducts and policies, with a view to ensuring consistency with the Anti-Corruption Directive’s harmonized definitions (e.g. against the broad notion of “undue advantage”)
    • Strengthening procurement and third-party due diligence controls, ensuring that intermediaries, agents, distributors, joint-venture partners, suppliers, clients and public-sector counterparts are properly screened and regularly monitored
    • Tracking and managing conflicts of interests
    • Reviewing internal procedures and tools to test their effectiveness
    • Reviewing or strengthening second and third level of controls, including audit, as related to the compliance function and framework within the company
    • Reinforcing training programs and internal reporting whistleblowing mechanisms to ensure alignment with and awareness of the revised legal framework.

    Acting now will enable organizations to transition more smoothly once the various European Member States align (where necessary) with this new legal framework.

    *Valeria Kiseleva (trainee) contributed to this article.

    Authors

    Fabio Cozzi

    Partner

    Milan

    Nicolette Kost De Sèvres

    Partner

    Washington, DC, Paris

    Arcangela Gerbino

    Associate

    Milan

    More insights

  • March 2026 alcohol industry update: Bribery charges, new state laws, and THC uncertainty

    ARTICLE / CLIENT ALERT

    March 2026 alcohol industry update: Bribery charges, new state laws, and THC uncertainty

    April 27, 2026

    Read time: 5 min

    Key takeaways
    Overview

    March 2026 brought significant developments for alcoholic beverage suppliers, distributors, and retailers, including a major federal indictment involving alleged commercial bribery, proposed legislative changes to alcohol distribution models in several states, and continued uncertainty surrounding hemp-derived tetrahydrocannabinol (THC) beverages. These developments signal heightened enforcement risk, potential structural shifts in state alcohol regulation, and ongoing compliance challenges for emerging product categories.

    In depth

    Federal enforcement developments

    On March 4, 2026, the US government filed a 10-count indictment tied to a premier beverage distributor, a grocery chain, and multiple suppliers, marking the most significant charging action to date involving alleged commercial bribery. Key points include the following:

    • The indictment charges six individuals, five of whom are current or former employees of the beverage distributor in the California Chain Division, with the sixth being an employee of a supplier. This is the first case to name the employees of a premier beverage distributor as defendants.
    • The government alleges that the beverage distributor’s employees, working with supplier representatives, paid bribes to employees of the grocery chain in exchange for favorable product placement and purchasing decisions.
    • The alleged bribes included prepaid gift cards, cash, luxury watches, suits, consumer electronics, sports equipment, golf outings, flights, hotel stays, and resort travel
    • According to the indictment, the defendants funded and concealed the bribes through third-party vendors that generated falsified invoices characterizing the payments as “marketing,” “merchandising,” “education,” and other legitimate expenses typically charging an additional fee of approximately 10%.
    • The indictment further alleges that the beverage distributor’s employees forged hotel folios to disguise bribe-related travel as legitimate business expenses and submitted them through the company’s finance office for reimbursement and bill-backs to suppliers.
    • The government alleges that the supplier employee provided $1,500 in gift cards and an all-expenses-paid trip to Las Vegas, including flights, hotel accommodations, cash, and entertainment
    • Following the indictments, California Alcoholic Beverage Control (ABC) Assistant General Counsel Robert de Ruyter publicly emphasized that criminal charges against individuals do not preclude future administrative actions by California ABC against the license holders that employ them

    Companies should review their promotional practices, third-party vendor agreements, and expense reimbursement procedures to minimize exposure. Key focus areas include strengthening internal controls, conducting thorough due diligence on intermediaries, ensuring transparent documentation of supplier bill-backs, and providing regular compliance training on permissible trade practices.

    State legislative and regulatory developments

    Several states are considering legislation that would significantly modify alcohol regulation, distribution frameworks, and beverage-related fees.

    • The Iowa House State Government Committee advanced HF2403, which would repeal Iowa Code § 123.22 and eliminate the state government’s monopoly over the importation and distribution of alcoholic liquor to retailers.
    • Iowa proposed HF809, which would repeal the state’s current bottle bill program, including the requirement that beverage containers sold in the state carry a five-cent refund value.
    • Colorado introduced Senate Bill 26-094, which would modify the state’s alternating proprietorship framework by allowing one licensee to manufacture, blend, bottle, and store alcohol on behalf of an adjacent licensee and by permitting distillers to participate in alternating proprietorships.
    • Colorado also introduced HB26-1271, which would have imposed a new impact and recovery fee on alcoholic beverages applicable to manufacturers and distributors, although the bill was postponed indefinitely in committee.
    • Michigan’s attorney general has filed a complaint in Michigan federal court against a brewing supply store for selling and shipping alcoholic products directly to consumers outside the state without a license, noting that the supplier misleads customers even though it has adequate licensing to sell and/or ship its products.

    Industry participants should monitor these legislative proposals closely and assess potential impacts on distribution strategies, operational costs, and market access. Iowa’s consideration of eliminating its state monopoly could fundamentally alter competitive dynamics and create new opportunities, while Colorado’s proposed alternating proprietorship reforms may enable craft producers to share facilities more efficiently. The Michigan enforcement action underscores the importance of maintaining proper licenses in every state where products are sold or shipped to consumers.

    Hemp THC beverage update

    At the National Alcohol Beverage Control Association’s Annual Legal Symposium, McDermott Will & Schulte Counsel Christine Dower led a panel on the legal and enforcement trends surrounding hemp THC beverages. Overall takeaways from the discussion include the following:

    • Regulatory uncertainty remains following President Trump’s signing in November 2025 of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act. Absent congressional action by November 12, 2026, hemp-derived THC beverages containing more than 0.4mg of hemp THC per container will be redefined as marijuana, currently a Schedule I controlled substance.
    • Multiple federal proposals have been introduced that would create oversight of hemp-derived cannabinoid products, including manufacturing standards, testing requirements, labeling rules, dosage limits, and age-gating provisions, though no unified federal framework has yet emerged.
    • At the state level, approaches continue to diverge, with some states advancing regulatory schemes, others moving to prohibit these products entirely, and several – , including Utah, Indiana, Oregon, New Mexico, and Wyoming – ending their legislative sessions without changes.
    • Panelists noted that consumers trust established alcohol regulatory systems, and hemp beverage advocates continue to push for a regulatory structure modeled on alcohol oversight.

    The November federal deadline and divergent state approaches create immediate compliance challenges and longer-term strategic uncertainty for the alcoholic beverage industry. Companies need to navigate potential conflicts between state permissibility and federal prohibition, manage exposure to rapidly shifting enforcement priorities, and prepare for multiple regulatory outcomes.

    Authors

    Alva C. Mather

    Partner

    Washington, DC

    Christine Dower

    Counsel

    Washington, DC

    Michelle L. Draper

    Senior Alcohol Regulatory Specialist

    Wilmington

    More insights

  • Reform of German Renewable Energy Sources Act 2027 – Key changes for project developers and investors in Germany

    Reform of German Renewable Energy Sources Act 2027 – Key changes for project developers and investors in Germany

    ARTICLE / CLIENT ALERT

    Reform of German Renewable Energy Sources Act 2027 – Key changes for project developers and investors in Germany

    April 27, 2026

    Read time: 17 min

    Key takeaways
    Overview

    Following the release of an initial unofficial draft version of the reform of the German Renewable Energy Sources Act 2027 (Erneuerbare-Energien-Gesetz, EEG) in February 2026, the German Federal Ministry for Economic Affairs and Energy (Bundesministerium für Wirtschaft und Energie) published a first official ministerial draft on 22 April 2026 and submitted it for consultation with industry associations.

    Below, we summarize key changes to the EEG in the ministerial draft version (EEG 2027-Draft Act) that will be important for project developers and investors in the renewable energy sector in Germany going forward.

    In depth

    1. Overview and objectives of the EEG 2027-Draft Act

    With the EEG 2027-Draft Act, the Federal Ministry for Economic Affairs and Energy is pursuing three core guiding principles: market orientation, cost efficiency, and grid compatibility.

    To implement these principles, the expansion of renewables in Germany is intended to consider the energy supply system as a whole to a greater extent than in the past, and to be more closely synchronized with the expansion of the electricity grid.

    The investment framework under the EEG 2027-Draft Act is intended to promote renewable energy in a market- and system-supportive manner while also dampening cost trends. Specifically, this is to be achieved through the abolition of fixed feed-in remuneration (Einspeisevergütung), the complete discontinuation of remuneration during periods of negative prices, and the end of financial support for smaller renewable energy plants with a capacity of less than 25 kW.

    The EEG 2027-Draft Act also contains further material amendments that have become necessary due to European requirements under the Electricity Market Regulation and state aid requirements of the European Commission. This includes, in particular, the introduction of a clawback mechanism (Contracts for Difference, CfDs).

    At the same time, the ministerial draft maintains the EEG’s existing target of increasing the share of electricity generated from renewable energy sources in gross electricity consumption to 80% by 2030. Accordingly, the expansion pathways (Ausbaupfade) are continued, with the resulting tender volumes largely maintained through 2032 and further increased for ground-mounted solar plants.

    2. Major change for all renewable energy plants: Introduction of a clawback mechanism (CfDs)

    a) New funding logic

    Project developers and investors should be prepared for a fundamental shift in the funding logic for subsidized renewable energy plants (i.e., those plants with an installed capacity of more than 100 kW and with the exception of biomass plants) under the EEG 2027-Draft Act, with a clawback mechanism to be introduced in Germany, in line with EU law requirements. Section 20a EEG 2027-Draft Act provides for a financing model for this mechanism, in the form of two-sided CfDs, under which plant operators will no longer be permitted to retain revenues that exceed the applicable tariff (anzulegender Wert).

    Under the CfD regime, in phases of higher electricity market prices the profits exceeding the applicable tariff will be clawed back. The draft ties into the existing market premium system and, as a general rule, maintains the existing model of subsidized direct marketing (geförderte Direktvermarktung) with production-dependent support. However, this model will in future be supplemented by a “refinancing contribution” (Refinanzierungsbeitrag) payable by the plant operator if the energy-source-specific annual market value (energieträgerspezifischer Jahresmarktwert) exceeds the applicable tariff.

    The new clawback mechanism set out in Section 20a(1) EEG 2027-Draft Act is based on calendar years. Accordingly, either a “clawback year” or a “support year” applies.

    The basic economic logic of the new CfD system will be as follows:

    • In years in which the energy-source-specific annual market value is higher than the applicable tariff that applies to the renewable energy plant, the plant operator must pay a refinancing contribution to the grid operator (“clawback year”).
    • In years in which the energy-source-specific annual market value is lower than the applicable tariff in the respective calendar year, the plant operator receives – as before – the market premium (Marktprämie) from the grid operator (“support year”).

    Where, under this logic, a clawback year applies, the plant operator must pay the refinancing contribution to the grid operator, and the grid operator is obliged to collect the refinancing contribution from the plant operator in order to ensure comprehensive collection and forwarding to the central EEG account.

    The future clawback mechanism applies to all “new plants” under the EEG 2027-Draft Act. This includes renewable energy plants that have received an EEG award in an EEG tender procedure with a bid date after 1 January 2027. For all other existing plants that were awarded under the current EEG or an older version of it, the existing market premium model without a clawback mechanism will continue to apply.

    b) Calculation of the refinancing contribution

    Whether a refinancing contribution must be paid by the plant operator is determined annually, retrospectively, for the preceding calendar year, in accordance with Annex 1 No. 4 to the EEG 2027-Draft Act, as follows:

    RB = JW – AW

    RB = refinancing contribution (Refinanzierungsbeitrag)

    JW = annual market value (Jahresmarktwert)

    AW = applicable tariff (anzulegender Wert)

    If, under this formula, a clawback year applies, the refinancing contribution is payable for each kilowatt-hour of electricity that is generated by the plant in such a clawback year and fed into the grid, with electricity quantities temporarily stored in Battery Energy Storage Systems (BESS) also being taken into account. While the earlier unofficial draft version of the EEG 2027 circulated in February still provided for a so-called “neutral corridor” above the applicable value (within which there would have been neither a entitlement to receive support nor an obligation to pay the refinancing contribution), under the EEG 2027-Draft Act, the refinancing contribution will now apply immediately once the annual market value exceeds the applicable value.

    This calculation formula is supplemented in the EEG 2027-Draft Act by additional, specific provisions. In particular, the refinancing contribution is to be adjusted in periods of low market revenues (Zeiten geringer Markterlöse). This adjustment is intended for situations in which the spot market price is positive throughout the clawback year, but where the price in individual quarter-hour intervals is so low that, after deducting its costs and paying the refinancing contribution, a plant operator can no longer generate a profit, and it would therefore be foreseeable that the operator would curtail production at the renewable energy plant despite the presence of a positive market value.

    In such situations, the refinancing contribution is to be reduced accordingly and is calculated as follows:

    RBadjusted = spot market price – minimum revenue

    Minimum revenues (Mindesterlöse) in cents/kWh are specified for:

    Solar plants: 0.5 ct./kWh

    Onshore wind energy: 1 ct./kWh

    The minimum revenue is intended to cover the plant operators’ ongoing costs and to provide an incentive to not curtail production at the renewable energy plant. The Federal Network Agency (Bundesnetzagentur) is also authorized to adjust the amount of these minimum revenues, although only increases (and not reductions) are permitted.

    c) Opt-out option

    The refinancing contribution is mandatory for all subsidized renewable energy plants. However, under the EEG 2027-Draft Act there is a one-time option to exit the EEG support regime and thus also the end the obligation to pay the refinancing contribution. The plant operator may notify the grid operator that it no longer wishes to receive support for the electricity generated by the plant going forward. This also eliminates the payment obligation for the refinancing contribution. Such declaration is final, however, and may only be made within the first 10 years after the commissioning of the respective renewable energy plants.

    d) Further relevant details

    As the opt-out option already demonstrates, the obligation to pay the refinancing contribution is directly linked to the receipt of EEG subsidies. This concept is also reflected in the following additional individual provisions:

    • The obligation to pay the refinancing contribution applies for a clawback period of 20 years from commissioning of the plant, i.e., in line with the tariff period.
    • Where EEG support is utilized only for a portion of the installed capacity, the obligation to pay the refinancing contribution likewise extends only to the electricity quantities generated with that portion.
    • During periods of negative spot market prices, the payment obligation for the refinancing contribution – just like the entitlement to EEG remuneration – is reduced to zero. These periods are aggregated into support and clawback periods on a quarter-hourly basis.
    • Under the EEG 2027-Draft Act, operators of subsidized renewable energy plants will continue to have the right to change the marketing form under the EEG on a monthly basis (without losing the EEG award, provided the opt-out option has not been exercised). In particular, operators will have the right to switch between subsidized direct marketing (market premium) and other direct marketing (sonstige Direktvermarktung, marketing via a PPA). However, the obligation to pay the refinancing contribution also applies to marketing by way of other direct marketing and thus is not tied to actual remuneration via the market premium: Instead, it already attaches to the general eligibility for EEG support, i.e., solely to the fact that the plant operator has the EEG award as a fallback option and can theoretically switch back into subsidized direct marketing at any time.

    3. Relevant changes for onshore wind energy

    a) Introduction of resilience auctions for onshore wind

    Due to EU law requirements, the EEG 2027-Draft Act introduces resilience auctions (Resilienzausschreibungen), which will also apply to onshore wind.

    The general objective of the resilience auctions is to strengthen the resilience of European industry and the energy supply and to reduce existing dependencies, or to counteract emerging new dependencies. However, the EEG 2027-Draft Act initially anchors only the core principles of this new auction category and sets the auction volumes (3,500 MW per year).

    Further details are to be determined subsequently in an ordinance, including, in particular, the detailed design of the qualitative award criteria (e.g., supply chain resilience, sustainability, and cybersecurity).

    b) Expansion path and auction volume

    • Continuation of the existing expansion path: The existing auction path for onshore wind also forms the basis of Section 4 of the EEG 2027-Draft Act. The objective of increasing installed capacity for onshore wind to 160 GW by 2040 remains unchanged.
    • Stabilization of the auction volume: For onshore wind, the current EEG provides for an annual auction volume of 10,000 MW per year through 2028. This auction volume will be maintained for the years 2029–2032.

    Under Section 28e EEG 2027-Draft Act, 3,500 MW per year are provided for the resilience auctions. These volumes are deducted from the auction volume for regular auctions for onshore wind. However, if volumes cannot be awarded in the resilience auctions, they are added back to the auction volume for regular auctions for onshore wind in the following year.

    c) New structure of auction dates

    As is currently the case under the existing legal framework, there will continue to be four auction dates per year for onshore wind. However, due to the introduction of the resilience auctions, the structure of the auction dates will change going forward, as one auction date will always be reserved for the resilience auction.

    In the introductory year, 2027, the resilience auction will take place on 1 August, and the regular auctions for onshore wind will take place on 1 February, 1 May, and 1 November. From 2028 onwards, the bid date of 1 February will be reserved for the resilience auctions, and the regular auctions will then take place on 1 May, 1 August, and 1 November.

    d) Further detailed changes for onshore wind

    • Adjustment of the start of remuneration: For awarded onshore wind turbines, the EEG realization period (Realisierungszeitraum) was previously extended to 36 months after publication of the award. However, the entitlement to receive remuneration under the EEG currently begins no later than 30 months after publication of the award (Section 36i EEG). This period will now be synchronized under the EEG 2027-Draft Act such that the start of remuneration will also occur no later than 36 months.
    • Fine-tuning in the reference yield model (Referenzertragsmodell): In Section 36h(1) EEG 2027-Draft Act, the correction factor (Korrekturfaktor) at the 50% site in the southern region is to be reduced, for reasons of cost efficiency, from 1.55 to 1.50.
    • Municipal participation: Even though municipal participation under Section 6 EEG is formulated across technologies, onshore wind turbines are a key use case for the financial participation of municipalities. Under the EEG 2027-Draft Act, the participation basis is shifted from the fed-in electricity quantity to the electricity quantity actually generated. Municipal participation eligibility is thus decoupled from the question of whether the electricity is consumed or stored in front of or behind the grid connection point, so that municipal participation is preserved even for self-consumption and storage concepts.

    4. Relevant changes for ground-mounted solar plants

    a) Introduction of resilience auctions for ground-mounted solar

    The new resilience auctions pursuant to Section 39n EEG 2027-Draft Act (see above) will be introduced not only for onshore wind but also for ground-mounted solar plants. For ground-mounted solar, an annual auction volume of 500 MW is set by law (Section 28e EEG 2027-Draft Act), which – just as with onshore wind – is credited against the regular auction volume (i.e., not auctioned in addition).

    b) Expansion path and auction volume

    • Continuation of the expansion path: The existing auction path for solar energy overall also forms the basis of Section 4 EEG 2027-Draft Act, and the objective of increasing installed solar capacity to 400 GW by 2040 remains unchanged. However, the EEG 2027-Draft Act shifts the focus of future development: In order to strengthen the cost efficiency of solar expansion, a stronger emphasis is to be placed on cost-effective ground-mounted solar plants, with less emphasis on rooftop solar plants. Accordingly, the previous “50% rooftop quota” in Section 4, sentence 2 of the EEG, under which at least half of solar installation must be attributable to rooftop plants, is deleted.
    • Increase of the auction volume: The EEG 2027-Draft Act provides for a significant increase in the auction volume for ground-mounted solar plants. Currently, the EEG provides for an annual auction volume of 9,900 MW for these plants in the years 2025 to 2029. Going forward, the annual auction volume in the years 2027 to 2032 is increased to 14,000 MW each year. In parallel, the EEG 2027-Draft Act reduces the volume for rooftop solar plants from 2,300 MW per year in the years 2026 to 2029 to only 1,500 MW per year in the years 2027 to 2032. The solar expansion path is thus clearly shifted in favor of ground-mounted solar plants.

    c) New structure of auction dates

    Against the background of the introduction of the resilience auctions, the number of auction dates for ground-mounted solar plants will be increased from three to four going forward. As is already the case under the current legal framework, the regular auctions for ground-mounted solar plants will take place on 1 March, 1 July, and 1 December. From 2027, an additional bid date for resilience auctions will be introduced on 1 September.

    d) Further detailed amendments for ground-mounted solar plants

    • Clarifications regarding aggregation of plants (Anlagenzusammenfassung): Section 24(2), sentence 3 of the EEG 2027-Draft Act introduces a clarification to the rules on aggregation of plants, which often have significant practical relevance for ground-mounted solar plants. Under this provision, a ground-mounted solar plant that is considered privileged in the outer area under planning law (Außenbereich) pursuant to Section 35(1) German Building Code, and a non-privileged ground-mounted solar plant that was constructed within the scope of a development plan (Bebauungsplan), will no longer be aggregated by law into a one single plant pursuant to Section 24(2) EEG.

    This legislative change is aimed at addressing cases in which non-privileged plants are “overtaken” during the development plan procedure by privileged plants, with the risk that, at the time of commissioning, they no longer are eligible to receive the payment entitlement (Zahlungsberechtigung) required for the EEG support due to the statutory rules of the aggregation of plants. Since operators of non-privileged plants will often not yet be aware of privileged plants whose project planning begins later than the time of their investment decision, the legislator considers the operator’s confidence in the investment sufficiently worthy of protection to justify an exception to the plant aggregation requirement, which remains generally applicable.

    • 50 MW cap: The maximum bid volume of 50 MW, already known from the EEG 2023, is confirmed under the EEG 2027-Draft Act and formulated consistently across segments. However, this rule remains subject to a state aid law condition precedent (cf. Section 102 EEG 2027-Draft Act), so it remains to be seen when this rule will start to apply. Pending the state aid approval long anticipated under the current EEG, the cap therefore continues to be 20 MW for the time being.

    5. Significance of BESS in the EEG 2027

    Battery Energy Storage Systems are not addressed in the EEG 2027-Draft Act as a standalone technology eligible for comprehensive support; rather, they are treated primarily as a system component to increase the flexibility of renewable energy plants and grids.

    The EEG regime is being reconfigured so that BESS are expected to be economically viable through market logic and grid relief, not through traditional EEG support. For this reason, the previous innovation auctions (Innovationsausschreibung) will be discontinued. Accordingly, there will be no direct support for BESS (in combination with renewable energy plants). Instead, the EEG 2027-Draft Act creates indirect incentives and effects for increased deployment of BESS.

    Key considerations include that:

    • BESS may become relevant under the future CfD logic, in particular to smooth revenue profiles. For example, BESS could be used to generate revenues in the economically most favorable time windows without triggering excessive clawback (e.g., by shifting generation/dispatch within the year).
    • The existing rules on negative prices will remain in force under the EEG 2027-Draft Act. As is the case today, BESS can be used during these periods to absorb excess electricity.
    • A storage component may also be of qualitative relevance in the new resilience auctions. Going forward, resilience auctions will be conducted based on qualitative criteria, including, among others, system stability. In projects, BESS can increase the likelihood of receiving an award as a qualitative resilience feature.

    6. Outlook and initial assessment

    The ministerial draft of the EEG 2027 will now undergo consultation with industry associations and will subsequently be introduced (potentially in a further revised version) into the parliamentary legislative procedure, which is not expected to be completed before the fall of this year.

    As the major EEG reforms in recent years have shown, further amendments are to be expected during the legislative procedure. The new EEG 2027 is scheduled to enter into force on 1 January 2027.

    Irrespective of possible further changes in the ongoing procedure, the now-published ministerial draft already makes sufficiently clear what major changes can be expected under the EEG 2027.

    Key changes include:

    • The focus of the new regulations on the introduction of the clawback mechanism with the refinancing contribution. Even though this comes as no surprise given European requirements, a paradigm shift in the EEG subsidy regime is now imminent: The familiar floor protection provided by the market premium will, in the future, be inextricably linked to a revenue cap through the obligation to pay the refinancing contribution. The profit margin for operators of renewable energy plants and investors will also therefore be narrowed in the future, and the economic upside potential during high-price phases will be limited.
    • For project developers and investors, the new CfD support framework therefore means that bid calculations in EEG tender procedures will need to be approached differently in the future (full-year price distribution, CfD cap, risk of high market values), and the business cases for Power Purchase Agreements (PPAs) and EEG options will change, particularly since a refinancing contribution will also be applied to the “other direct marketing” (i.e., via PPAs) in the future. The opt-out option will also take on new strategic significance, particularly for the structuring of PPA projects. In addition, the new clawback mechanism will increase regulatory and billing complexity (such as calculation at quarter-hour intervals, direct marketing, and data management) and requires professional structures and IT systems.

    At the same time, it is clear that the EEG 2027 will continue to provide a reliable investment framework for renewable energy in Germany. For existing plants, the CfD provisions will not apply due to the constitutionally anchored principle of protection of trust (Vertrauensschutzprinzip). Moreover, investments in new plants will offer opportunities, given long-term stable expansion targets and continued auction volumes for onshore wind and ground-mounted solar plants.

    The future focus on more cost-effective ground-mounted solar plants is also likely to strengthen the “utility-scale solar” segment. However, this raises the question of how the recently significantly undersubscribed EEG auctions can be made more attractive again in order to restore the investment viability of ground-mounted solar plants. Notably, the ministerial draft also does not address how the recently significantly oversubscribed wind auctions are to be handled. There is a pressing need for remedial measures to bring to life the large number of permitted wind projects that have recently been unsuccessful in EEG auctions.

    We will keep you informed of further developments regarding the EEG 2027. Please feel free to contact us at any time if you have questions regarding the planned changes.

    Authors
    More insights

  • IRS roundup: April 13 – April 17, 2026

    IRS roundup: April 13 – April 17, 2026

    ARTICLE

    IRS roundup: April 13 – April 17, 2026

    Apr 24, 2026

    Read time: 3 min

    Check out our summary of significant Internal Revenue Service (IRS) guidance and relevant tax matters for April 13, 2026 – April 17, 2026.

    April 13, 2026: The IRS issued Notice 2026-26, providing updated monthly interest rates for pension funding calculations, including the corporate bond yield curve, spot segment rates under § 417(e)(3), and 24-month average segment rates under § 430(h)(2). The notice also provides the 30-year Treasury rate for March 2026 (4.85%) and related weighted average rates used in determining minimum funding requirements.

    April 13, 2026: The IRS issued Revenue Procedure 2026-19, providing updated domestic asset/liability percentages and investment yields used by foreign insurance companies to compute minimum effectively connected net investment income under § 842(b) for 2025. The guidance sets the domestic asset/liability percentages at 128.2% for foreign life insurers and 202.4% for foreign property and casualty insurers, with corresponding domestic investment yields of 2.1% and 2.2%, respectively.

    The revenue procedure also provides instructions for calculating estimated tax and installment payments, requiring taxpayers to use these updated percentages and yields when determining minimum effectively connected net investment income and reflects data derived from 2023 tax return information.

    April 13, 2026: The IRS issued Revenue Ruling 2026-8, providing updated Standard Industry Fare Level rates and the terminal charge for valuing noncommercial flights on employer-provided aircraft under § 61 and Treasury Regulation § 1.61-21(g). Starting January 1 through June 30, 2026, the ruling sets the terminal charge at $54.48 and establishes mileage rates of $0.2980 (up to 500 miles), $0.2272 (501 to 1,500 miles), and $0.2184 (more than 1,500 miles), which are used to calculate the taxable value of this fringe benefit.

    April 16, 2026: The IRS issued Revenue Ruling 2026-9, providing monthly applicable federal rates (AFRs) for May 2026, including short-, mid-, and long-term rates under § 1274, as well as adjusted AFRs, § 382 rates, and low-income housing credit percentages. The ruling also sets the § 7520 rate at 5.00% for determining present value calculations.

    The IRS also released its weekly list of written determinations (e.g., Private Letter Rulings, Technical Advice Memorandums, and Chief Counsel Advice)

    Recent court decision

    April 15, 2026: A federal district court in Texas held that the IRS exceeded its statutory authority in designating certain micro-captive insurance arrangements as “listed transactions” under § 6707A, finding that the agency failed to demonstrate that such transactions are presumptively tax-avoidant. Relying on Loper Bright, the court emphasized that it must exercise independent judgment in determining the limits of the IRS’s statutory authority, rejecting any deference to the agency’s interpretation and focusing on whether the regulations fell within the outer bounds of Congress’s delegation. The court concluded that § 6707A requires a meaningful distinction between transactions that merely have the potential for abuse and those that are more likely than not tax-avoidant and found that the administrative record did not support the heightened standard required for listed transactions. The court therefore declared Treasury Regulation § 1.6011-10 invalid and vacated it.

    However, the court upheld the IRS’s authority to classify similar arrangements as “transactions of interest” under Treasury Regulation § 1.6011-11, concluding that the IRS reasonably established its potential for tax abuse and satisfied Administrative Procedure Act requirements.

    In depth
    Authors

    Kai M. Fenty

    Associate

    Chicago

    More insights
    Endnotes

  • CLO transactions: Spring 2026 market trends and regulatory developments

    CLO transactions: Spring 2026 market trends and regulatory developments

    ARTICLE / CLIENT ALERT

    CLO transactions: Spring 2026 market trends and regulatory developments

    April 24, 2026

    Read time: 13 min

    Key takeaways
    Overview

    The US and European markets for collateralized loan obligation securities (CLOs) in 2025 carried the momentum of a robust 2024 through headwinds from tariff announcements and trade wars and two notorious private credit defaults that led to speculation about wider deterioration in the debt space.

    Despite unease about the assets underlying CLOs, interest rate spreads continued to tighten throughout the year in both the underlying assets and CLO debt. Persistent headlines during the first quarter of 2026 focusing on withdrawal requests by investors in credit funds and the enforcement, in some instances, of gates to manage outflows has led to a pullback in the CLO market.

    Although the regulatory burden was perceived to have eased in the United States during 2025, two pronouncements from EU regulators surprised and jolted the CLO market.

    Key Takeaways

    • Resilient but uneasy market: CLOs remain active with tightening spreads despite rising credit concerns and isolated defaults.
    • Shift in equity dynamics: Lower returns are pushing the market toward captive equity.
    • CLO ETFs: ETFs are driving demand potentially affecting pricing.
    • Increasing regulatory complexity: Diverging US, EU, and UK rules are creating new compliance challenges.
    • Private credit under scrutiny: Growth continues, but defaults, redemptions, and liquidity concerns are drawing market attention.
    In depth

    CLO market holds firm amid headwinds, but equity pressures mount

    The CLO market successfully navigated several headwinds during 2025. On the supply side, 2025 was the second-highest year on record for broadly syndicated loan (BSL) issuance, but the BSL market was dominated by refinancings. Similar trends occurred in private credit. On the demand side, CLO issuance remained robust in 2025.  Spreads tightened throughout the year and new issue, reset and refinancing volume for both BSL and private credit CLOs exceeded or fell just short of 2024’s record levels.

    The CLO market expected the Trump administration to be pro-growth, but it has been a mixed bag for the CLO market. Opportunistic borrowers took advantage of declining interest rates and re-priced or refinanced their outstanding debt. However, the resulting spread compression and relative loan price stability reduced returns to CLO equity, which made BSL CLO equity a less attractive investment to equity arbitrage investors, reinforcing the movement away from third-party equity to captive equity funds by CLO managers.

    Due in part to (a) limited new loan supply in the BSL space, (b) equity return models remaining low, and (c) a perceived diminishing of foreign investment interest, momentum in the new issue market was subdued during the first quarter of 2026. That said, many CLO refinancings, resets, and new issuances from 2024 will exit their non-call periods in 2026 which, presuming economic growth and that interest rates stabilize, should foreshadow increased refinancing and reset activity later this year.

    CLO ETFs: Market growth, structural volatility and liquidity risks

    The rise of exchange-traded funds (ETFs) designed to invest in CLO securities continued in 2025. According to a report by 9fin, inflows to CLO ETFs totaled $15 billion as of December 15, 2025, contributing to a market that has grown from $120 million in assets under management in 2020 to more than $30 billion today.  Demand for CLO ETFs remained strong for most of 2025, but by October the tide had turned and weekly outflows from CLO ETFs exceeded $500 million due to investor concern regarding corporate credits.

    ETFs are essentially mutual funds with shares that trade on exchanges and can be acquired by retail investors through a broker. Unlike the share price of a traditional mutual fund, which is set daily, the share price of an ETF may fluctuate during the trading day. A CLO ETF can therefore experience price volatility that may not correlate with the pricing attributable to the pool of CLO securities underlying the ETF or general pricing in the CLO market.

    CLO ETFs generally purchase their investments in the secondary market, but the largest CLO ETFs also purchase in the primary market, and the demand from CLO ETFs appears to be lowering CLO pricing, according to S&P Global. Although the largest CLO ETFs have focused on acquiring AAA notes issued by BSL CLOs, newer CLO ETFs target investing in more junior portions of the capital structure of BSL CLOs and in middle-market CLOs.

    Trading of CLO tranches that underlie CLO ETFs is thin compared to shares owned by a typical equity ETF. But this lack of liquidity in the assets does not impact the ability to trade ETF shares. Unlike an open-ended mutual fund, which may be forced to sell assets to meet investor redemptions, ETFs are not obligated to sell investments. Rather, the ETF investors simply sell their shares on an exchange. A CLO ETF sell-off may therefore not directly impact the pricing of CLO tranches in the secondary market. In fact, an ETF’s share price can deviate from its net asset value per share (NAVPS), although trading of the ETF shares and the ability of market participants to create or redeem ETF shares tend to reconcile NAVPS and the ETF’s share price.

    Turbulence ahead: Private credit faces scrutiny as it grows in the CLO market

    Middle-market (MM)/private credit and BSL CLOs represent two segments of the leveraged finance market, differing primarily in the borrower size of the underlying loans, structure and liquidity. BSL CLOs issue large tranches of debt, which are rated and fairly liquid. MM CLOs are smaller and often relationship driven. Although their debt is also rated, MM CLOs typically offer higher yields to compensate for lower liquidity. The BSL CLO market was above $600 billion in 2025, while the MM CLO market was much smaller at approximately $150 billion but growing.

    BSL CLOs are collateralized by loans to large corporations, typically with higher EBITDA compared to middle-market borrowers, which are widely traded and publicly rated. Information about these loans is more readily available, so there is an argument that BSL CLOs are more transparent than MM CLOs. MM CLOs are collateralized by loans to smaller, private companies, often with EBITDA below $100 million. The loans are typically originated by the portfolio manager and/or its affiliates and are not publicly rated, instead requiring credit estimates from rating agencies. Middle market loans often feature stronger maintenance-based covenants compared to the “covenant-lite” nature of broadly syndicated loans.

    In BSL CLOs, managers focus on portfolio management and trading to navigate credit conditions, with the primary benefit to the manager being the payment of management fees and, if certain goals are satisfied, an incentive fee. Managers of MM CLOs use them to finance their direct lending business (which may involve business development companies or private investment funds).

    We have recently seen a convergence between MM CLOs and BSL CLOs as private credit has grown. Some MM CLOs are increasingly owning larger upper middle-market loans, some middle-market funds have refinanced broadly syndicated loans in workouts, and some MM CLO managers are raising third-party equity for arbitrage.

    In late 2025 the bankruptcies of an auto parts manufacturer and a subprime auto lender shook the private credit markets. In October 2025, JPMorgan CEO Jamie Dimon warned that these bankruptcies were signs of lax corporate lending practices in private credit, stating, “[W]hen you see one cockroach, there are probably more.” Even after this, the private credit markets and MM CLOs forged ahead as many investors attributed these bankruptcies to company-specific issues, rather than the private credit sector in general, and in April 2026 Dimon said that he was not worried that the risks posed by private credit were “systemic.”

    Several high-profile private credit managers have been in the news recently because investors have made unprecedented redemption requests, and in some cases, managers have exercised gates that limit redemptions to specified percentages over time. The underlying speculation about these redemption requests ranges from fears that artificial intelligence will threaten the business model of software companies and concerns about conflicts in the Middle East to investors (in many cases, retail investors new to holding these types of less-liquid investments) questioning the market value of private credit portfolios. This has all predictably invited more scrutiny of private credit.

    CLO documentation trends reflect ongoing debt-equity tension

    CLO indenture documentation continued to evolve in 2025, reflecting a modest drift toward more debt-protective terms across a range of new issue and refinancing transactions, although outcomes varied considerably by manager and by specific provisions. Debt investors in several transactions appear to have negotiated more protective outcomes in areas such as concentration limitations, reinvestment period length, and par flush mechanics. At the same time, equity investors have negotiated to retain provisions allowing CLOs to participate in financial instruments issued in loan management exercises, creating flexibility in partial class-specific refinancings and adding the flexibility to designate an interim payment date during post-reinvestment periods to allow for distribution of cash, rather than holding it in eligible investments pending distribution.

    As with any single-year snapshot, conclusions about the direction of CLO documentation should be drawn with care. Indenture terms continue to be actively negotiated, and the balance between debt and equity protections remains a live issue for all market participants.

    US regulatory landscape: Assessing compliance mandates, capital reclassifications and perceived easing in oversight

    Corporate Transparency Act

    The US Corporate Transparency Act (CTA), part of the Anti-Money Laundering Act of 2020, requires (by regulations promulgated by the applicable regulatory bodies) the reporting of certain beneficial owner information to the Financial Crimes Enforcement Network (FinCEN). During March, 2025, FinCEN issued an Interim Final Rule, which was effective immediately upon publication in the Federal Register, narrowing the scope of reporting required under the CTA and its implementing regulations to exclude reporting from domestic reporting companies and US persons (although requiring foreign reporting companies to provide beneficial ownership information for non-US persons) and reducing the scope of reporting about US individuals by foreign pooled investment vehicles (if required to report due to being registered to do business in a US state or tribal jurisdiction).

    SEC’s proposed revisions to the Custody Rule

    In 2023, the SEC proposed revisions to its Custody Rule, which the agency referred to as the Safeguarding Rule. As initially proposed, the Safeguarding Rule would impose significant costs and burdens on CLO managers and completely alter the relationship with CLO custodians. A proposed expansion of the definition of “assets” from “funds and securities” to “funds, securities, or other positions held in a client’s account” would include interests in loans and loan participations. As drafted, the rule also would impose requirements to engage a “qualified custodian” and mandate audit requirements and liability standards. After receiving numerous comments and strong resistance from the industry, the SEC withdrew the proposals in June 2025. Future regulatory action on this topic must now start with a new proposal and a fresh public comment period. As of this writing, the SEC has not made a new Safeguarding Rule proposal, nor is it clear when or if a new proposal will be issued.

    SEC securitization conflicts of interest proposal

    In November 2023, the SEC adopted Securities Act Rule 192 to prohibit conflict of interest transactions in connection with the issuance of asset-backed securities (ABS). ABS transactions, including CLOs, in which the closing of the sale of the ABS occurred on or after June 9, 2025, became subject to compliance with the rule in 2025. CLO managers, arrangers, and other market participants focused during the year on evaluating the scope of the rule and implementing policies and procedures designed to ensure compliance.

    NAIC regulatory developments

    The Risk-Based Capital Investment and Evaluation (E) Working Group of the National Association of Insurance Commissioners (NAIC) has been reviewing the regulatory framework governing insurers’ investments in structured securities. Included in that effort is a proposed reassessment of risk-based capital (RBC) treatment for CLO securities and the development of a model for assigning NAIC designations and corresponding capital charges.

    The primary issues relating to the CLO market are the NAIC’s purported anxiety with reliance on external credit ratings and the potential for “capital arbitrage,” where the capital treatment for securitized tranches may, due to the ratings, be more favorable than holding the underlying assets directly. CLO industry participants, particularly the Loan Syndication and Trading Association (LSTA), have engaged with the NAIC to provide the industry view on the proposed changes and the timeline for implementation. As insurers are significant investors in the CLO market, significant increases in these capital requirements would create a significant headwind for CLOs.

    Other developments

    In December 2025, the Office of the Comptroller of the Currency (OCC) and the Federal Deposit Insurance Corporation (FDIC) rescinded their participation in the Interagency Guidance on Leveraged Lending (issued in 2013 with the Federal Reserve Board), which the OCC and FDIC stated resulted in significant growth in leveraged lending market share by nonbanks. The Federal Reserve Board has not yet rescinded the guidance that applies to banking institutions that it regulates.

    The SEC issued a “No Objection” letter in December 2025, confirming that the agency will not object to the accounting treatment of CLO loan tranches (meeting certain criteria) as “receivables” for regulatory capital purposes.  This guidance was predicated on several factors, one of which was that the loan tranche would not be convertible into securities issued by the CLO.  This has caused investors in CLO loan tranches to exclude conversion features from the terms of these loans.

    In March 2026, the staff of the SEC’s Division of Investment Management issued guidance clarifying that investments by registered funds in CLO debt securities do not count toward the 10% limitation applicable to investments in funds as set forth in the SEC’s Rule 12d1-4 under the Investment Company Act of 1940.

    EU and UK regulatory activity shaping the CLO compliance landscape

    European bodies delivered two shocks to the CLO market in 2025.

    First, the European Supervisory Authorities issued a report declaring that the “originator sole purpose test,” used to determine whether an originator entity may serve as a risk retention holder for EU purposes, should focus on asset revenue percentage (rather than the percentage of assets on the balance sheet) and that 50% of the revenue of the risk retainer should come from non-securitized assets (widely interpreted to exclude risk retention holdings).

    Second, a European Banking Authority Q&A answer from the European Commission noted that a conditional sale agreement, a widespread method used by CLO managers to qualify as originators, would not satisfy the originator requirements for a risk retention holder. As a result, the market has largely switched to forward purchase agreements to document a paper purchase of assets by the CLO manager prior to the forward sale to the CLO (where settlement typically occurs).

    The securitization regimes in the EU and UK remain subject to review, and amendments are expected to be implemented in the future. For the EU regime there will likely be a lightening of reporting obligations, but it is unclear whether there will be amendments to any risk retention definitions or clarification of the originator sole purpose test.

    In the UK, regulators are currently consulting on changes to the securitization framework and may have more flexibility to implement market-friendly changes, which could result in greater divergence between the EU and UK rules.

    Conclusion

    The CLO market currently reflects a complex mix of resilience and recalibration. Strong technical demand and innovation – particularly through ETFs and private credit structures – are offset by emerging credit concerns, evolving investor behavior, and regulatory uncertainty. As the market adapts, participants must navigate shifts in capital sources and a fragmented regulatory landscape, while remaining alert to signs of broader credit deterioration.

    If you have questions regarding opportunities, challenges, the regulatory landscape, or other aspects of the evolving CLO market, please contact your McDermott Will & Schulte lawyer or the authors of this alert.

    Authors

    Phillip J. Azzollini

    Partner

    New York – 919 Third Avenue

    Joseph Gambino

    Partner

    New York – 919 Third Avenue

    Daniel V. Oshinsky

    Partner

    New York – 919 Third Avenue

    Vera Quagliato

    Partner

    New York – 919 Third Avenue

    Martin Sharkey

    Partner

    London – One Eagle Place

    Sunho (Sam) Shin

    Partner

    New York – 919 Third Avenue

    Craig Stein

    Partner

    New York – 919 Third Avenue

    James Zhu

    Senior Associate

    London – One Eagle Place

    More insights

  • FinCEN imposes record $80 million penalty on Canaccord Genuity

    FinCEN imposes record $80 million penalty on Canaccord Genuity

    ARTICLE / CLIENT ALERT

    FinCEN imposes record $80 million penalty on Canaccord Genuity

    April 23, 2026

    Read time: 6 min

    Key takeaways
    Overview

    On March 6, 2026, the US Department of the Treasury’s Financial Crimes Enforcement Network (FinCEN), in coordination with the US Securities and Exchange Commission (SEC) and the Financial Industry Regulatory Authority (FINRA), assessed an $80 million penalty against broker-dealer Canaccord Genuity LLC for violations of the federal anti-money laundering (AML) laws, including the Bank Secrecy Act (BSA) and its implementing regulations. The enforcement action is notable not only because it is the largest penalty assessed against a broker-dealer for AML violations, but also because of the close coordination among FinCEN, the SEC, and FINRA, the detailed nature of the regulator findings, and the egregiousness of the facts. The sizable civil money penalty reflects the severity of compliance failures and the risk to the market for allowing those failures to continue.

    Below, we highlight notable aspects of the FinCEN, SEC, and FINRA releases.

    In depth

    FinCEN consent order

    FinCEN issued a consent order assessing an $80 million civil money penalty against Canaccord, which provided wholesale market making for over-the-counter (OTC) low-price securities and trade execution for institutional customers. As part of the resolution of the enforcement action, Canaccord admitted several violations of federal AML laws.

    First, FinCEN found that Canaccord willfully failed to implement and maintain an AML program that adequately managed the exposure from its high-risk OTC market-making business line, violating 31 U.S.C. § 5318(h) and 31 C.F.R. § 1023.210. Surveillance reports designed to identify suspicious trading went unreviewed. Further, two compliance employees admitted they had falsified records to appear as though they had completed the required reviews. Second, FinCEN determined that Canaccord failed to conduct sufficient customer due diligence (CDD) on foreign correspondent accounts, violating 31 U.S.C. § 5318(i) and 31 C.F.R. § 1010.610. Canaccord onboarded and maintained such accounts without obtaining key information about business purpose, expected activity, or jurisdictional risks and failed to perform ongoing monitoring. To the extent it did collect documents, Canaccord did not conduct further evaluation or any ongoing due diligence to maintain customer information and risk profiles. Third, FinCEN identified at least 160 instances where Canaccord failed to file suspicious activity reports (SARs), violating 31 U.S.C. § 5318(g) and 31 C.F.R. § 1023.320. This included transactions later revealed to be part of pump-and-dump schemes, as well as numerous other instances where Canaccord failed to appropriately investigate and act upon red flags, including matched trades, prearranged trades, rapid deposit and liquidation patterns, domination of trading volume of a security, and marking the close.

    FinCEN found these violations to be egregious because of their volume and because the AML deficiencies were not cured despite regulators repeatedly identifying issues. As early as 2013, FINRA had identified deficiencies in Canaccord’s AML program and suggested increased use of electronic and automated reports, which Canaccord committed to implementing. However, a 2016 FINRA analysis of a sample of transactions found that compliance reviews of flagged trades continued to be inadequate. Canaccord again committed to enhancing its AML program but failed to do so.

    In addition to the monetary penalty, Canaccord agreed to hire a qualified independent consultant to conduct a SAR lookback review to identify other instances of noncompliance.

    SEC cease-and-desist order

    Simultaneously with the FinCEN consent order, the SEC issued a cease-and-desist order imposing sanctions against Canaccord for the same conduct cited by FinCEN. The SEC found that Canaccord willfully violated Section 17(a) of the Exchange Act and Rule 17a-8 by failing to file approximately 150 SARs.[1]

    Like FinCEN, the SEC found Canaccord’s misconduct to be egregious because it occurred despite repeated regulatory guidance issued by FinCEN and FINRA that highlighted red flags relevant to Canaccord’s microcap and penny stock valuation and trading business, emphasizing the need for robust monitoring of such transactions.[2]

    FINRA letter of acceptance, waiver, and consent

    Finally, FINRA named Canaccord in a letter of acceptance, waiver, and consent (AWC) stemming from the same conduct described in the FinCEN and SEC orders. The AWC detailed wide‑ranging violations of FINRA rules, including Rule 3310 (failure to develop and implement a written AML program reasonably designed to achieve compliance with the BSA), Rule 3110 (failing to implement a supervisory system to ensure compliance with AML rules), Rule 8210 (submitting falsified documents), Rule 5310 (failing to comply with best execution rules), Rule 5260 (trading through halts), Rule 5320 (trading ahead of customers), Rule 6460 (undue delays in execution and display of orders), and Rule 2010 (violations of standards of commercial honor).[3]

    FINRA also noted that Canaccord relied on an underqualified and severely understaffed trading compliance group that “failed to review most of the firm’s surveillance reports for extended periods,” with some delays lasting years.

    Additionally, FINRA faulted Canaccord for its failure to address these violations following numerous prior warnings. For example, FINRA warned Canaccord following AML examinations that its suspicious activity surveillance was deficient in 2014, that its completion of surveillance reviews and monitoring of foreign correspondent accounts were deficient in 2017, and that it failed to remediate the issues identified in the 2014 review in 2018.

    Canaccord submitted a statement of corrective action describing steps it had taken to address the issues identified by FINRA, including increasing AML staffing, exiting the OTC market-making business, closing the majority of foreign customer accounts, and retaining independent consultants to conduct a comprehensive review of its AML program, which included a SAR lookback and enhancements to its onboarding due diligence process. Despite these significant actions, FINRA assessed a $20 million fine against Canaccord.

    Conclusion

    In the wake of these actions, broker-dealers and other financial institutions should evaluate their AML programs to ensure their effectiveness and remediate any previously identified problems. Financial institutions should also verify that their AML programs are appropriately resourced given the risks presented by the business, both with respect to staffing and training. The FinCEN and SEC orders, along with FINRA’s AWC, emphasize that high-risk business models require proportionate AML efforts and that CDD and ongoing monitoring must be rigorous and risk based. Entities should carefully review:

    • Staffing and resources for AML compliance capabilities
    • Onboarding due diligence processes
    • Suspicious trading activity surveillance policies and reporting
    • AML policies and procedures specific to high-risk business lines
    • Prior guidance received from federal regulators to confirm implementation

    Our lawyers have decades of experience helping financial institutions comply with AML requirements and handling examinations and enforcement actions. If you have questions or if you would like to discuss whether your AML program is sufficiently resourced, appropriately tailored to your business, or otherwise vulnerable to enforcement, please contact your regular McDermott Will & Schulte lawyer or the authors of this alert.

    Authors

    Melissa G.R. Goldstein

    Partner

    New York – 919 Third Avenue

    Sagar K. Ravi

    Partner

    Washington, DC, New York – One Vanderbilt Avenue

    Betty Santangelo

    Counsel

    New York – 919 Third Avenue

    Kyle B. Hendrix

    Associate

    Washington, DC

    R. Bray McDonnell

    Associate

    Washington, DC

    More insights

  • International Arbitration Laws and Regulations 2026

    International Arbitration Laws and Regulations 2026

    ARTICLE

    International Arbitration Laws and Regulations 2026

    March 26, 2026

    Read time: 2 min

    Key takeaways
    Overview

    In this chapter, featured in Global Legal Insights, Milo Molfa, Jack Thorne, and James McGlaughlin examine how the traditional notion of international arbitration as a neutral and depoliticised process is increasingly challenged by modern geopolitical tensions, including sanctions and state-driven economic and other protective measures.

    Using a case study linked to EU sanctions against Russia, they explore how such pressures can disrupt arbitral proceedings and require more strategic management, including reliance on interim measures and court support.

    Read on globallegalinsights.com >

    In depth
    Authors

    Milo Molfa

    Partner

    London – 22 Bishopsgate

    Jack Thorne

    Partner

    London – 22 Bishopsgate

    James McGlaughlin

    Senior Associate

    London – 22 Bishopsgate

    More insights

  • Tax considerations for distressed companies: Entity structure and cancellation of debt income

    Tax considerations for distressed companies: Entity structure and cancellation of debt income

    ARTICLE / CLIENT ALERT

    Tax considerations for distressed companies: Entity structure and cancellation of debt income

    April 22, 2026

    Read time: 6 min

    Key takeaways
    Overview

    In these uncertain times, some companies are exploring ways to restructure their existing credit facilities to navigate business challenges, including cash flow shortages. Highly leveraged companies that are taxed as partnerships, such as the portfolio companies of private equity funds, must carefully consider the significant tax consequences associated with restructuring and modifying their debt obligations, especially if the company is or is likely to be in financial distress. One of the most common and important tax issues that must be considered during a debt restructure is the potential recognition of cancellation of debt (COD) income. There are exclusions that limit the recognition of COD income. In the context of distressed companies, the most common of these are bankruptcy and insolvency. The availability and impact of the bankruptcy and insolvency exclusions depend on the borrower’s entity classification.

    In depth

    COD income and exclusions

    Generally, a borrower will recognize ordinary income when debt is discharged for less than its adjusted issue price. Recognition of COD income is generally not required if the borrower’s debt is discharged through a formal bankruptcy proceeding. Similarly, an insolvent borrower is not required to recognize COD income – but only to the extent of the borrower’s insolvency (i.e., the excess of the borrower’s liabilities over the fair market value of its assets, determined immediately before the debt discharge). A borrower availing itself of one of these exclusions is required to make corresponding reductions to certain of its tax attributes (e.g., net operating losses, passive activity losses, and basis).

    Critically, the application of such exclusions depends on the borrower’s tax classification. For corporations and entities classified as corporations (including S corporations), bankruptcy and insolvency are tested at the entity level. Thus, if the debt of a corporate borrower is discharged in bankruptcy, the borrower does not recognize COD income. If the corporate borrower is insolvent, it excludes COD income to the extent of its insolvency. Accordingly, the attributes of a corporate borrower’s shareholders are irrelevant to the determination of the amount of COD income required to be recognized by the corporate borrower.

    For tax partnerships, however, bankruptcy and insolvency determinations are made at the partner level. This distinction can lead to materially different tax results. A partnership may be economically insolvent, yet each partner may still be taxed on its allocable portion of the partnership’s COD income if such partner is not bankrupt or if it is solvent. Yet a corporate borrower may exclude COD income based solely on its own financial condition without regard to its shareholders.

    Partnership incorporation

    In general

    Because of such disparity, distressed tax partnerships might consider restructuring to be taxed as a corporation in advance of a future debt discharge. Such a restructuring can ring-fence the income tax consequences associated with a complete or partial debt discharge to the corporate borrower where the bankruptcy or insolvency exclusion may be available, notwithstanding the financial condition of its shareholders. However, identifying the income tax consequences associated with such a restructuring requires a facts-and-circumstances analysis and careful planning. Factors to consider include, among others, the following:

    • Future prospects of the business
    • Identification of the entity that is legally obligated to repay the debt
    • Determination of whether a debt discharge is imminent or an eventuality
    • Determination of whether the restructuring itself qualifies for nonrecognition tax treatment
    • Determination of whether the restructuring will be respected under general tax principles based on the facts and circumstances

    S corporation election

    S corporations can, in some cases, provide a middle-ground structure. As with C corporations, bankruptcy and insolvency are tested at the S corporation level. S corporation income and loss are passed through to the shareholders, so an S corporation is generally not subject to corporate-level income tax. Accordingly, to the extent the bankruptcy or insolvency exclusion is applicable to exclude all or part of COD income resulting from a debt discharge, such excluded COD income does not pass through to the S corporation’s shareholders or increase each shareholder’s basis in their S corporation stock.

    Restructuring tax risks

    While restructuring in view of COD concerns can be relatively easy to achieve (e.g., filing Form 8832 to treat an LLC as a corporation), there are important risks to consider. For example, converting a tax partnership into a corporation (whether by state law conversion or entity classification election) can trigger immediate taxable gain to the partners. Generally, transfers (or deemed transfers) of assets to a corporation are treated as tax-free exchanges provided that certain requirements are satisfied. However, if liabilities transferred (or deemed transferred) to a corporation exceed the adjusted tax basis of the assets transferred to the corporation, such excess is treated as taxable “boot” to the transferring shareholder. This risk is often material when restructuring a distressed tax partnership and, in some cases, may offset the restructuring’s intended tax benefits. Timing also matters because transactions undertaken shortly before a debt discharge (particularly if undertaken closely to a discharge and principally to alter tax results) may be subject to IRS challenge under various theories.

    Additional technical tax issues may arise when restructuring a distressed partnership. In tax partnerships, COD income is allocated among partners under the partnership agreement. Meanwhile, reductions in partnership liabilities are treated as deemed cash distributions that can trigger taxable gain if such deemed cash distribution to a partner exceeds that partner’s adjusted tax basis in its partnership interest. When a partner is also a lender to the partnership and that loan (recourse to the partner-lender) is fully or partially forgiven, such partner will receive an allocation of the COD income (ordinary income) but may only be able to recognize a capital loss with respect to the bad debt (unless the partner-lender is in the trade or business of lending).

    Debt-for-equity exchanges can also generate COD income if the value of the equity issued is less than the amount of the debt being satisfied (for corporations, measured by the fair market value of the equity issued, and for partnerships, which may, if conditions are met, use liquidation value under an IRS safe harbor). S corporations must take care to avoid violating eligibility rules, such as the single-class-of-stock requirement, which can be inadvertently triggered during a debt workout.

    Conclusion

    The tax consequences of a workout are highly sensitive to both structure and timing. While changes in an entity’s tax classification can potentially mitigate COD-related tax exposure, such changes should be evaluated early and based on available facts and circumstances, determining the likelihood of a future debt discharge, and carefully structured to avoid unintended tax results.

    Authors

    Andrew M. Granek

    Partner

    New York – One Vanderbilt Avenue

    Akiva B. Ungar

    Associate

    Chicago

    Gregory Weigand

    Counsel

    Miami, New York – One Vanderbilt Avenue

    More insights